LivaNova PLC Announces CEO Transition: Damien McDonald to Succeed André-Michel Ballester
(Thomson Reuters ONE) -
LONDON, Nov. 02, 2016 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN)
("LivaNova" or the "Company"), a market-leading medical technology and
innovation company, today named Damien McDonald as the company's new Chief
Executive Officer (CEO) and board member, effective January 1, 2017. McDonald
currently serves as LivaNova's Chief Operating Officer, and will succeed André-
Michel Ballester, who will resign effective December 31, 2016.
Ballester served as CEO of Sorin S.p.A. ("Sorin") from 2007 to 2015, prior to
the October 2015 merger of Sorin and Cyberonics, Inc. ("Cyberonics") to create
LivaNova.
"On behalf of the LivaNova Board of Directors, I would like to thank André-
Michel for his highly successful 12-year career with LivaNova and Sorin. André-
Michel integrated two remarkable companies into one, creating a stronger and
well-positioned medical-device company with significant opportunities for
growth," said Dan Moore, Chairman of the Board. "Damien's background and
credentials are ideally suited to assume leadership of LivaNova. The Board is
highly confident in his ability and readiness to further develop and deliver on
LivaNova's mission to continue to improve health worldwide."
McDonald was recently appointed COO, joining LivaNova from Danaher Corporation
where he was Group Executive and Corporate Vice President leading a $1.5-billion
group of dental consumables companies. Earlier in his tenure he was Group
President of Kerr where he and his team focused on building a strong research
and development pipeline while improving operational performance utilizing the
Danaher Business System. Additionally, he previously led Zimmer's spine division
where he demonstrated his leadership skills, attracting a strong executive team
that created a growth trajectory for the business unit. Earlier in his career,
he worked with J&J's Medical Device Franchises, including Ethicon, where he
led marketing of the $2.5-billion medical device unit.
"I am honored to succeed André-Michel, and I want to thank him for his service
and substantial contributions," said McDonald. "LivaNova is united in its
passion, focus and commitment in serving our customers and patients around the
world. I wish to thank the Board for their vote of confidence in me leading this
great company and express my firm commitment to grow the business through
advancing medical technology and transforming lives."
About LivaNova
LivaNova PLC is a global medical technology company formed by the merger of
Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and
Cyberonics Inc., a medical device company with core expertise in
neuromodulation. LivaNova transforms medical innovation into meaningful
solutions for the benefit of approximately 4,600 employees worldwide and is
headquartered in London, U.K.
For more information, please visit www.livanova.com, or contact:
Investor Relations and Media
Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications(at)livanova.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LivaNova PLC via GlobeNewswire
Datum: 02.11.2016 - 11:31 Uhr
Sprache: Deutsch
News-ID 504303
Anzahl Zeichen: 3872
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"LivaNova PLC Announces CEO Transition: Damien McDonald to Succeed André-Michel Ballester"
steht unter der journalistisch-redaktionellen Verantwortung von
LivaNova PLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
